A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer